Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II palbociclib in second-line advanced sarcomas with CDK4 overexpression
2016-004039-19Phase 2Active
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in soft tissue sarcoma (STS) and osteosarcoma (OS), sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Progression-free survival rate at 6 months. Started Dec 2016; status: active.
02
Drugs
palbociclib
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on 2016-004039-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004039-19.